An observational study in Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd and Patients With HER2-low Advanced Breast Cancer Treated With T-DXd, sponsored by Yeon Hee Park. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Yeon Hee Park · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 618 studies in Breast Neoplasms with a site in Korea, Republic of — 132 open to participants now, 230 under way, 75 of them phase 3. Breast Neoplasms · Korea, Republic of.
Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, this one is the 90th largest by planned enrollment of the 109 observational ones that give a count, is one of 39 that started in 2025, is one of 110 observational ones, reaches primary completion later than 83 of the 229 other live ones, and was the 588th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →132 of the 618 studies in Breast Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Korea, Republic of, United States, Belgium and 5 more countries
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+ · Women only
AstraZeneca · Sites in Korea, Republic of, United States, France and 6 more countries
Ages 18–130
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, Canada and 6 more countries
Ages 18+
BeOne Medicines · Sites in Korea, Republic of, United States, Australia and 13 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
618 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 104 · Phase 2 182 · Phase 3 177 · Phase 4 14
First in 2001; this study’s year is marked. 39 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 218 across the 505 interventional studies, 444 across the 109 observational. Of the 304 that completed or were terminated, 148 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
348 of 618 have an industry lead sponsor. The 10 most frequent:
Yeon Hee Park is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Yeon Hee Park has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
44 of the studies in Breast Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 14 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT05440149Phase 3Seoul National University HospitalThe Postoperative Radiotherapy in N1 Breast Cancer Patients | 2026-12-31 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
Add all 44 to your calendar (.ics) → With an account.
Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is a prospective, observational, multicenter cohort study evaluating the efficacy and safety of NEPA (netupitant/palonosetron) in patients with HER2-positive or HER2-low advanced breast cancer treated with T-DXd
The observation period of this study is until the discontinuation after administration of T-Dxd or until 8 Cycle.
Primary objectives: to evaluate the efficacy and safety of NEPA for CINV prevention in advanced breast cancer patients receiving at least 2 cycles of T-DXd across all defined assessment periods (acute, delayed, overall, long-delayed, and extended overall phases).
Patients who had not been previously treated with T-DXd and are scheduled to receive their first cycle of T-DXd with NEPA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who agree to use highly effective methods or not of . Highly effective contraception methods include:
A. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
B. Total hysterectomy (surgical removal of the uterus and cervix) or tubal ligation (getting your "tubes tied") at least six weeks before taking study treatment.
C. Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject.
D. Combination of the following:
I. Placement of an intrauterine device (IUD) or intrauterine system (IUS) II. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
advanced breast cancer patients receiving at least 2 cycles of T-DXd.
Complete response (CR: no emesis and no rescue medication)
CR during the long-delayed phase(\>120-504 hours)
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks
Complete response (CR: no emesis and no rescue medication)
CR during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), extended overall phase (0-504 hours)
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks
Complete control (CC: no emesis, no rescue medication and no or mild nausea)
CC during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), long-delayed phase (\>120-504 hours), and extended overall phase (0-504 hours)
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks
Total control (TC: no emesis, no rescue medication and no nausea)
TC during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), long-delayed phase (\>120-504 hours), and extended overall phase (0-504 hours)
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 day), assessed up to 6 weeks
No significant nausea (NSN: defined as no or mild nausea)
NSN during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), long-delayed phase (\>120-504 hours), and extended overall phase (0-504 hours
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 day), assessed up to 6 weeks
No nausea
No nausea during the acute phase (0-24 hours), delayed phase (\>24-120 hours), overall phase (0-120 hours), long-delayed phase (\>120-504 hours), and extended overall phase (0-504 hours)
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 day), assessed up to 6 weeks
CR rate
Daily CR rate
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks
NSN rate
Daily NSN rate
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks
no nausea rate
Daily no nausea rate
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks
Proportion of patients who receive rescue medications
Proportion of patients who receive rescue medications
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks
Proportion of patients undergoing T-DXd dose delay
Proportion of patients undergoing T-DXd dose delay due to nausea and/or vomiting
Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks
Proportion of patients requiring permanent discontinuation
Proportion of patients requiring permanent discontinuation of T-DXd due to nausea and/or vomiting
Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks
Health-related quality of life (EQ-5D-5L)
1. Range of EQ-5D index Minimum-Maximum Range: approx.-0.28 to -0/17 \~ 1,000 2. Range of EQ VASMinimum-Maximum Range: 0\~100 \*The higher to score, the better the health status.
Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks
FACIT Fatigue
Proportion of patients experiencing fatigue and severity of fatigue (FACIT Fatigue) (1) Range of FACIT Fatigue scale Minimum-Maximum Range 0\~52 \*Higher score indicate less fatigue and better health status.
Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks
CTCAE v5.0
Safety evaluated according to CTCAE v5.0, higher scores mean a worse outcome
Time frame: At the end of first documented progression or first Cycle 8 of T-DXd (each cycle is 28 days), assessed up to 24 weeks
Daily rescue medication rate
Daily rescue medication rate
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks
Duration of rescue medication
Duration of rescue medication
Time frame: At the end of first Cycle 2 of T-DXd (each cycle is 28 days), assessed up to 6 weeks
Plan to share: Undecided — It will be decided later.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Jun 2026, 10 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 10 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yeon Hee Park